Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avadomide (Primary) ; Fluvoxamine; Itraconazole; Rifampicin
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Liver cancer; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 06 Jun 2019 Results assessing drug-drug interaction to study effect of cytochrome P450 inhibition and induction on the pharmacokinetics of the Avadomide in healthy adult subjects published in the Journal of Clinical Pharmacology
    • 28 Feb 2018 Status changed from not yet recruiting to completed.
    • 16 Nov 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top